stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Return on invested capital
Takeda Pharmaceutical Co.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2026 (0.03%). Over the past ten years it has ranged from −3.64% (fiscal 2015) to 17.7% (fiscal 2021); the current reading is higher than 17% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 0.03% | (1.91) |
| FY2025 | 1.94% | 0.79 |
| FY2024 | 1.15% | (1.86) |
| FY2023 | 3.01% | (0.14) |
| FY2022 | 3.15% | (14.57) |
| FY2021 | 17.7% | 17.04 |
| FY2020 | 0.68% | (0.58) |
| FY2019 | 1.26% | (4.49) |
| FY2018 | 5.75% | 2.17 |
| FY2017 | 3.58% | (0.10) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| UTHR United Therapeutics Corporation compare | 30.1% |
| ZTS Zoetis Inc. compare | 19.6% |
| NBIX Neurocrine Biosciences, Inc. compare | 17.7% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.77% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.09% |
| ELAN Elanco Animal Health Incorporated compare | 0.51% |
| TAK Takeda Pharmaceutical Co. | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. compare | −0.02% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement